ADMA Biologics (ADMA) News
NASDAQ: ADMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
13.17-0.17 (-1.27%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ADMA news summary
We found 8 recent headlines mentioning ADMA Biologics (ADMA): 0 in the past week and 7 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, ADMA is down 1.27% at $13.17. The most recent story, "ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?", was published by Nasdaq on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest ADMA Biologics headlines
- ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?ADMA Biologics gains 20.9% after strong Q3 results, as surging Asceniv sales and a raised 2026 profit outlook offset Bivigam weakness and competitive pressures.NasdaqADMA, GRFS, TAK
- ADMA Biologics (ADMA) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqADMA, ET
- ADMA Biologics hits 10-month high as Asceniv drives Q3 beatSeeking Alpha
- ADMA Biologics Q3 Profit Jumps 37%; Reiterates FY26 Revenue Outlook, Stock Up 23%(RTTNews) - Biologics, Inc. (ADMA), a commercial-stage biopharmaceutical company focused on specialty plasma-derived biologics, reported third-quarter 2026 financial results, with higher earnings and…NasdaqADMA, BRK.A
- Adma Biologics reiterates at least $530M 2026 revenue and raises minimum adjusted EBITDA to at least $275M as ASCENIV demand acceleratesSeeking Alpha
- ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-YearGlobeNewswire
- ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026Conference Call Scheduled for November 4, 2026, at 4:30 p.m. ET Conference Call Scheduled for November 4, 2026, at 4:30 p.m. ETGlobeNewswire
- ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing ProcessOptimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG YieldGlobeNewswire